Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEEp OCEAN Study
NCT06719141Phase 3Active, not recruiting
- Sponsor
- Longboard Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of bexicaserin in developmental and epileptic encephalopathy (DEE), sponsored by Longboard Pharmaceuticals. Started Nov 2024; status: active, not recruiting.
02
Drugs
bexicaserin
03
Conditions
developmental and epileptic encephalopathy (DEE)
Beyond the preview
Go deeper on NCT06719141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719141.